BDRX - Midatech Pharma Plc
IEX Last Trade
4.38
0 0%
Share volume: 23
Last Updated: Thu 26 Dec 2024 08:23:30 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$4.38
0.00
0.00%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
12.29%
1 Month
-10.64%
3 Months
1,354.00%
6 Months
410.63%
1 Year
67.55%
2 Year
48.91%
Key data
Stock price
$4.38
DAY RANGE
$4.35 - $4.38
52 WEEK RANGE
$0.28 - $10.89
52 WEEK CHANGE
$63.09
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Stephen A. Stamp
Region: US
Website: midatechpharma.com
Employees: 20
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: midatechpharma.com
Employees: 20
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Midatech Pharma plc focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme. MTX114, an immuno-suppressant for topical application in psoriasis, MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder.
Recent news